2025-05-28 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc (TDOC) based on the provided data, focusing on key metrics and recent developments.

**Report: Teladoc Health Inc (TDOC)**

Teladoc Health Inc is a telehealth company providing virtual healthcare services.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (TDOC):** -69.47%
*   **Cumulative Return (VOO):** 84.28%
*   **Absolute Divergence:** -153.75%
*   **Relative Divergence:** 1.7

**Analysis:** TDOC has significantly underperformed the S&P 500. The absolute divergence is substantial, and the relative divergence indicates TDOC is currently positioned near the lower end of its historical performance range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha   | Beta   | Cap(B) |
|------------|----------|----------|---------|--------|--------|
| 2015-2017  | 76.0%    | 60.6%    | 49.0%   | -0.0   | 6.1    |
| 2016-2018  | 128.0%   | 59.3%    | 110.0%  | 0.0    | 8.7    |
| 2017-2019  | 176.0%   | 59.3%    | 147.0%  | 0.4    | 14.7   |
| 2018-2020  | 237.0%   | 64.0%    | 211.0%  | 0.2    | 35.1   |
| 2019-2021  | -83.0%   | 64.0%    | -138.0% | 0.2    | 16.1   |
| 2020-2022  | -295.0%  | 81.3%    | -301.0% | 0.0    | 4.2    |
| 2021-2023  | -488.0%  | 81.3%    | -505.0% | -0.6   | 3.8    |
| 2022-2024  | -111.0%  | 81.3%    | -128.0% | -0.9   | 1.6    |
| 2023-2025  | -40.0%   | 72.9%    | -71.0%  | -0.8   | 1.2    |

**Analysis:**  The table highlights a drastic decline in performance in recent years.  CAGR has turned negative. Alpha is consistently negative, indicating underperformance relative to the benchmark.  Beta has fluctuated but is generally low or negative, suggesting a weak correlation with the market. MDD(Max DrawDown)가 증가한것을 고려했을 때 위험이 커졌으며, Cap(B)가 감소했다는 것은 시가총액이 감소했다는 의미이다

**2. Recent Price Action**

*   **Current Price:** $7.08
*   **Previous Close:** $6.81
*   **Change:** 3.96%
*   **5-day Moving Average:** $7.02
*   **20-day Moving Average:** $7.15
*   **60-day Moving Average:** $7.73

**Analysis:** The price shows a recent uptick, exceeding the 5-day moving average, but still below the 20-day and 60-day averages.  The 3.96% change from the previous close suggests a potential short-term rebound.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 55.95
*   **PPO:** 0.0891
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.38)
*   **Delta_Previous_Relative_Divergence:** 0.0 (단기하락)
*   **Expected Return (%):** -5387.1

**Analysis:** The MRI indicates low market risk. The RSI of 55.95 is neutral. The PPO is slightly positive. The Hybrid Signal suggests a cautious buy signal. The negative Delta_Previous_Relative_Divergence는 단기하락를 의미한다. Expected Return이 매우 낮다는 것은 장기적인 투자에 있어서도 전망이 좋지 않다는 것을 의미한다. 급반등(3.96%)이 있었지만, 다른 지표들이 좋지 않아 일시적인 현상으로 보인다

**4. Recent News & Significant Events**

*   **May 28, 2025:** Major business developments, regulatory changes, or market events.
*   **May 25, 2025:** Analyst discussions on recent performance and outlook.
*   **May 26, 2025:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **May 27, 2025:** Market experts highlighting risks and opportunities, advising monitoring of news and announcements.

**Analysis:** Recent news indicates volatility and significant events impacting TDOC. Investors should monitor news closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-01 | -0.53 | 0.63 B$     |
| 2024-10-31 | -0.19 | 0.64 B$     |
| 2024-08-01 | -4.92 | 0.64 B$     |
| 2024-04-26 | -0.49 | 0.65 B$     |
| 2025-05-01 | -0.49 | 0.65 B$     |

**Analysis:** The EPS is negative, indicating losses. Revenue has been relatively stable.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.63B  | 68.73%        |
| 2024-12-31 | $0.64B  | 70.50%        |
| 2024-09-30 | $0.64B  | 71.94%        |
| 2024-06-30 | $0.64B  | 70.73%        |
| 2024-03-31 | $0.65B  | 69.89%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $1.43B  | -6.52%   |
| 2024-12-31 | $1.49B  | -3.25%   |
| 2024-09-30 | $1.51B  | -2.21%   |
| 2024-06-30 | $1.50B  | -55.77%  |
| 2024-03-31 | $2.29B  | -3.58%   |

**Analysis:** Revenue has been relatively stable. Profit margins are high but are offset by negative ROE. Equity has decreased, indicating potential financial strain.

**7. Overall Analysis**

TDOC has significantly underperformed the S&P 500. While there has been a recent price increase, EPS is negative, equity is decreasing, and recent news suggests volatility. The MRI indicates low market risk, but the negative expected return is a cause for concern.  The Hybrid Signal suggests a cautious buy, but overall, the indicators suggest caution. 장기 투자에 있어서 신중하게 접근해야 할 것이다
